Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Treasury Shares (2016 - 2026)

Myriad Genetics has reported Treasury Shares over the past 12 years, most recently at $7.1 million for Q4 2025.

  • Quarterly Treasury Shares rose 33.96% to $7.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2025, up 33.96% year-over-year, with the annual reading at $7.1 million for FY2025, 33.96% up from the prior year.
  • Treasury Shares was $7.1 million for Q4 2025 at Myriad Genetics, down from $7.5 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $7.6 million in Q2 2025 and troughed at $3.1 million in Q4 2021.
  • The 5-year median for Treasury Shares is $4.7 million (2023), against an average of $4.9 million.
  • Year-over-year, Treasury Shares skyrocketed 78.95% in 2021 and then decreased 8.93% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $3.1 million in 2021, then increased by 19.35% to $3.7 million in 2022, then grew by 18.92% to $4.4 million in 2023, then rose by 20.45% to $5.3 million in 2024, then surged by 33.96% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Treasury Shares are $7.1 million (Q4 2025), $7.5 million (Q3 2025), and $7.6 million (Q2 2025).